Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. The prescribing information for rimegepant (Nurtec ® ODT) has been updated to include clinical lactation data. Rimegepant is ...

Calcitonin gene–related peptide receptor has been implicated in the pathogenesis of migraine. Rimegepant is an orally administered, small-molecule, calcitonin gene–related peptide receptor antagonist ...

The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for rimegepant (Nurtec™ ODT; Biohaven) for the preventive treatment of migraine. The sNDA is ...

A recently study of rimegepant, an investigational oral calcitonin gene–related peptide receptor (CGRP) blocker for migraine, resulted in a higher percentage of patients relieved of pain over placebo.

The evaluation committee considered evidence submitted by Pfizer, a review of this submission by the external review group (ERG), and responses from stakeholders. See the committee papers for full ...

NEW HAVEN, Conn., May 18, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), announced today that it will present data from 25 accepted abstracts demonstrating the ...

The use of the calcitonin gene-related peptide (CGRP) antagonist rimegepant 75 mg for 52 weeks showed a favorable safety profile and sustained benefits for migraine prevention in a new open-label ...

Rimegepant, made by Pfizer, could help 145,000 sufferers a year as health watchdog recommends oral treatment on the NHS Laura Donnelly is the Health Editor for The Telegraph, leading award-winning ...

The final draft guidance recommends rimegepant for adults who have at least four migraine attacks per month, but less than 15 The final draft guidance recommends rimegepant for adults who have at ...

NEW HAVEN, Conn., March 12, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company (NYSE: BHVN) today announced that NURTEC™ ODT (rimegepant) is now available by prescription in U.S. pharmacies.

(RTTNews) - Biohaven Pharmaceutical Holding Co. Ltd. (BHVN) and Pfizer Inc. (PFE) announced Tuesday a strategic commercialization arrangement for rimegepant in markets outside of the U.S., upon ...